Stay updated with breaking news from Celcuity Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers are comparing gedatolisib plus fulvestrant, with or without palbociclib, to standard treatment for HR+, HER2- advanced breast cancer.
Tradition Wealth Management LLC boosted its position in Celcuity Inc. (NASDAQ:CELC – Free Report) by 92.5% during the 1st quarter, Holdings Channel.com reports. The fund owned 3,850 shares of the company’s stock after buying an additional 1,850 shares during the quarter. Tradition Wealth Management LLC’s holdings in Celcuity were worth $39,000 at the end of […]
Celcuity Inc. (NASDAQ:CELC – Get Free Report) saw a significant growth in short interest in July. As of July 31st, there was short interest totalling 2,670,000 shares, a growth of 7.7% from the July 15th total of 2,480,000 shares. Based on an average trading volume of 88,900 shares, the short-interest ratio is presently 30.0 days. […]
Celcuity (NASDAQ:CELC – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Needham & Company LLC in a report issued on Friday, Benzinga reports. They presently have a $25.00 price target on the stock. Needham & Company LLC’s target price indicates a potential upside of 152.78% from the stock’s previous close. […]
Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity Second Quarter 2023 Earnings Conference Call. At this time, all lines are in a listen-only mode.